GLP-1 analogue therapy for obesity in people from Asia
Obesity and overweight has become prevalent in Asian populations. It is estimated that 1 billion people across Asia have a BMI higher than 25 kg/m2,1 and that one in three people in China has obesity. Economic development, increased accessibility of foods, changes in dietary pattern, and reductions in physical activity have driven increases in obesity prevalence from 2007 to 2017.2 This trend shows no sign of slowing down, and it has perhaps been aggravated by behavioural change associated with the COVID-19 pandemic and resulting lockdowns.